BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, February 6, 2026
Home
»
Authors
» Aaron Lorenzo
Aaron Lorenzo
Articles
ARTICLES
Phytobiotech Raises C$17M For Plant-Derived Molecules
Sep. 26, 2002
By
Aaron Lorenzo
StemCells Cutting Back To Focus On Neural, Liver Disease
Sep. 24, 2002
By
Aaron Lorenzo
StemCells Cutting Back To Focus On Neural, Liver Disease
Sep. 24, 2002
By
Aaron Lorenzo
eXegenics, IDDS Merging Via Stock Deal Valued At $46M
Sep. 23, 2002
By
Aaron Lorenzo
eXegenics, IDDS Merging Via Stock Deal Valued At $46M
Sep. 23, 2002
By
Aaron Lorenzo
Endovasc Creates Subsidiaries For Two Late-Stage Products
Sep. 20, 2002
By
Aaron Lorenzo
Endovasc Creates Subsidiaries For Two Late-Stage Products
Sep. 20, 2002
By
Aaron Lorenzo
Cellegy Resurrects Cellegesic, Set To Begin Third Phase III
Sep. 10, 2002
By
Aaron Lorenzo
Cellegy Resurrects Cellegesic, Set To Begin Third Phase III
Sep. 10, 2002
By
Aaron Lorenzo
LION Cutting Back On Drugs To Focus On Support Systems
Sep. 9, 2002
By
Aaron Lorenzo
View All Articles by Aaron Lorenzo
